PHG•Philips reported Q3 2026 sales of EUR 4.4 billion and operating income of EUR 165 million. It recorded a EUR 288 million provision related to Respironics investigations and reiterated its full-year free cash flow outlook of EUR 1.5–1.7 billion.
Philips reported Q3 2026 sales of EUR 4.4 billion and income from operations of EUR 165 million. Operating cash flow rose to EUR 544 million, while free cash flow increased to EUR 384 million.
Respironics reached an agreement in principle with the US Department of Justice over recall investigations. Philips recorded a EUR 288 million provision.
Philips reiterated its full-year 2026 outlook, including free cash flow of EUR 1.5–1.7 billion.
